Abstract
Basal cell carcinoma is a slow-growing, locally invasive tumor. Locally it can be aggressive, destroy neighboring tissues, cause ulceration and invade deep into cartilage and bone. It is considered a chronic disease because many cases that develop their first basal cell carcinoma will subsequently develop at least one additional tumor, and a group of cases have more than one basal cell carcinoma at the time of diagnosis. HeberFERON is the combination of alpha2b and gamma IFNs with antiproliferative, antiangiogenic and immunomodulatory activity. It is a therapeutic modality used in the treatment of basal cell carcinoma and could have a remote effect on the rest of the tumors.
Subject
General Medicine,General Chemistry
Reference10 articles.
1. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines;Peris;European Journal of Cancer,2019
2. Sánchez Linares V, Cifuentes Suarez JP, Martínez Cuervo JJ, et al. Carcinoma basocelular del rostro tratado con HeberFERON. Gac Méd Espirit. 2019;21(2):87-97.
3. Álvarez Castillo A, Rodríguez Alfaro JM, Salas Boza A. Revisión sistemática del carcinoma basocelular. Rev méd sinerg. 2020;5(5):e483.
4. González Sánchez N, Armada Esmores Z, Llópiz Casanova L. Propiedades de los interferones y su acción antitumoral. Medicent Electrón. 2017;21(3).
5. López Pupo N, Manganelly Fonseca Y, Tablada Robinet ME, et al. Utilidad del HeberFERON® en pacientes con carcinoma basocelular. Medisan. 2021;25(6):1297.